Drugs / C106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05427253 | Jun 2022 → Jun 2023 | idiopathic pulmonary fibrosis, pulmonary hypertension | Vicore Pharma AB | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-10-27 | Vicore Pharma AB | Results Vicore provides update regarding Phase 1 study of C106 vicorepharma.com ↗
While there were no major safety signals or tolerability concerns in the doses tested, an increase in blood pressure was observed at twice-daily doses of 140 mg and higher. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-10-27 | Vicore Pharma AB | Vicore provides update regarding Phase 1 study of C106 vicorepharma.com ↗ |
| 2022-06-16 | Vicore Pharma AB | Vicore announces first human dosed with novel ATRAG, C106 vicorepharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05427253 ↗ |
| Action | Activate | “selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist” NCT05427253 ↗ |
| Route | Oral | “multiple ascending oral doses of C106” NCT05427253 ↗ |